Meeting News

Yutiq reduces recurrence of posterior segment uveitis

Quan Dong Nguyen

CHICAGO — Treatment with a single intravitreal injection of Yutiq can significantly reduce recurrence rates of noninfectious uveitis affecting the posterior segment, according to a speaker here.

“Patients with uveitis of the posterior segment who receive one fluocinolone acetonide implant throughout a 36-month period are more likely to achieve and maintain inflammation control. They are less likely for the need of systemic or local rescue therapy, and have a better chance of resolution of macular edema,” Quan Dong Nguyen, MD, MSc, said at the American Society of Retina Specialists annual meeting.

The controlled, prospective, double-masked, multicenter trial randomized 87 patients with recurrent noninfectious posterior segment uveitis to receive a 0.18 mg fluocinolone acetonide insert (Yutiq, EyePoint Pharmaceuticals) and 42 patients to receive sham treatment.

At 36 months, 42% of treated subjects required IOP lowering medications compared with 33% of sham participants. However, 85% of treated participants with macular edema at baseline experienced resolution compared with 70% of sham participants, Nguyen said.

“Over a 36-month period there was an overall gain of 9.1 letters for those who received the fluocinolone implant compared to 2.5 letters for those randomized to the sham group,” Nguyen said.

IOP lowering surgeries were required in 5.7% of treated participants compared with 11.9% of sham participants. Additionally, 73.8% of treated participants required cataract surgery compared with 23.8% of sham participants. – by Robert Linnehan

Reference:

Nguyen QD. 36-Month outcomes of injectable fluocinolone acetonide intravitreal insert on recurrences of non-infectious posterior segment uveitis. Presented at: American Society of Retina Specialists annual meeting; July 27-30, 2019; Chicago.

Disclosure: Nguyen reports he is an advisor for EyePoint Pharmaceuticals.

Quan Dong Nguyen

CHICAGO — Treatment with a single intravitreal injection of Yutiq can significantly reduce recurrence rates of noninfectious uveitis affecting the posterior segment, according to a speaker here.

“Patients with uveitis of the posterior segment who receive one fluocinolone acetonide implant throughout a 36-month period are more likely to achieve and maintain inflammation control. They are less likely for the need of systemic or local rescue therapy, and have a better chance of resolution of macular edema,” Quan Dong Nguyen, MD, MSc, said at the American Society of Retina Specialists annual meeting.

The controlled, prospective, double-masked, multicenter trial randomized 87 patients with recurrent noninfectious posterior segment uveitis to receive a 0.18 mg fluocinolone acetonide insert (Yutiq, EyePoint Pharmaceuticals) and 42 patients to receive sham treatment.

At 36 months, 42% of treated subjects required IOP lowering medications compared with 33% of sham participants. However, 85% of treated participants with macular edema at baseline experienced resolution compared with 70% of sham participants, Nguyen said.

“Over a 36-month period there was an overall gain of 9.1 letters for those who received the fluocinolone implant compared to 2.5 letters for those randomized to the sham group,” Nguyen said.

IOP lowering surgeries were required in 5.7% of treated participants compared with 11.9% of sham participants. Additionally, 73.8% of treated participants required cataract surgery compared with 23.8% of sham participants. – by Robert Linnehan

Reference:

Nguyen QD. 36-Month outcomes of injectable fluocinolone acetonide intravitreal insert on recurrences of non-infectious posterior segment uveitis. Presented at: American Society of Retina Specialists annual meeting; July 27-30, 2019; Chicago.

Disclosure: Nguyen reports he is an advisor for EyePoint Pharmaceuticals.

    See more from American Society of Retina Specialists Meeting